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Introduction
Atrial fibrillation (AF) is the most common dys-
rhythmia, affecting an estimated 2.2 million adults
in the United States, and it is projected that this
number will soar to 5.6 million affected people by
the year 2050 [1, 2]. Risk factors for the develop-
ment of AF include advanced age, diabetes, hyper-
tension, heart failure, valvular heart disease, coro-
nary artery disease, left ventricular dysfunction,
wide pulse pressure, excessive alcohol consump-
tion, obstructive sleep apnea and personality traits
such as anger and hostility [2–8]. Patients with un-
controlled and untreated AF are at higher risk for
stroke and death and a variety of other adverse out-
comes [3, 9]. In order to minimize the adverse ef-
fects of AF, considerable time, money and effort is
spent in trying to maintain sinus rhythm. How-
ever, we have learned from the AFFIRM study (the
Atrial Fibrillation Follow-up Investigation of
Rhythm Management) that in patients with AF
a treatment strategy of rhythm compared to rate
control offered no mortality benefit [10, 11]. The re-
sults of the AFFIRM trial reinforced the inadequa-
cies of achieving and maintaining normal sinus
rhythm with the pharmacologic therapies that are
currently available to us. Given the limitations of
pharmacotherapy, alternative strategies using inva-
sive catheter based and/or surgical ablation of AF
has gained popularity.
Our understanding of the pathophysiology, the
mechanisms initiating and maintaining AF, has
undergone considerable change over the past
30 years. In 1998 Haissaguerre et al. [12] published
a landmark paper describing focal ectopic atrial foci
in the pulmonary veins that preceded paroxysmal
AF (PAF), the radiofrequency ablation of which
quelled the atrial foci, restoring normal sinus
rhythm in some patients. Experimental studies
have also demonstrated small reentrant circuits
called rotors that are distributed throughout the
atria forming a hierarchical distribution of frequen-
cies [13, 14]. Catheter ablation in the anatomic area
containing the dominant frequency, also known as
the mother rotor, has shown reasonable success in
terminating cases of PAF and chronic AF [13, 14].
Based on these pivotal studies, both catheter and
surgical ablation of AF attempt to isolate the pulmo-
nary veins from the remainder of the left atrium and
target areas of fractionated atrial electrograms and
dominant frequencies within the left atrium in an
effort to restore and maintain normal sinus rhythm.
Several goals and benefits are desired with
surgical AF ablation. The major goal of AF ablation
is the restoration of atrioventricular (AV) synchro-
ny, which often translates into hemodynamic im-
provements particularly in those with left ventricu-
lar dysfunction. Patients typically have less anxie-
ty and an improved sense of well being while in
normal sinus rhythm, leading to improved quality
of life and exercise tolerance. Re-establishing nor-
mal bi-atrial contraction reduces the duration of
stasis within the left atrium and the left atrial ap-
pendage thereby lowering the risk of cardioembol-
ic events and occasionally obviating the need for
chronic anticoagulant therapy. Ideally, one would
like to achieve the aforementioned goals with min-
imal risk. In addition to the common risks inherent
in invasive procedures, some of the described and
potentially lethal complications of catheter and sur-
gical AF ablation include atrio-oesophageal fistula
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formation and myocardial ischemia or infarction as
a result of injury to the left circumflex artery which
runs in the atrioventricular groove usually embed-
ded within the epicardial fat pad [15–17].
In this review, we describe the history of sur-
gical AF ablation, review the contemporary meth-
ods and energy sources used in surgical AF treat-
ment and describe the advantages and disadvantag-
es of various techniques and energy sources.
Left atrial isolation
In 1980, Williams et al. [18] described a proce-
dure called ‘left atrial isolation’ performed initially
for the treatment of difficult to map atrial tachycar-
dias but adapted later for the treatment of AF. The
procedure confined AF to an isolated portion of the
left atrium while the remainder of the heart could
be activated by the sinus node. Despite restoration
of sinus rhythm, ongoing anticoagulation was re-
quired for the isolated portion of the left atrium,
which remained in AF. Prior to the implementation
of the left atrial isolation procedure, difficult to con-
trol AF necessitated surgical His bundle ablation
and permanent pacemaker placement.
In 1982, a catheter based ablation of the His
bundle using catheter fulguration was described by
Scheinman et al. [19], which, having undergone
multiple revisions, is the basis for today’s catheter
based ablation of the AV node, obviating the need
for surgical His bundle ablation.
Corridor procedure
In 1985, a brief abstract by Guiraudon et al. [20]
described an open-heart procedure in five dogs,
called the corridor procedure. The procedure was
proposed as an alternative to His bundle ablation
and involved isolation of the left atrial free wall fol-
lowed by isolation of the sinus node from the right
atrium. An area of atrial tissue was corridored to
the atrial septum containing the AV node. The util-
ity of the corridor procedure was limited by ongo-
ing requirements for anticoagulation and the lack
of AV synchrony.
Maze I, II, III procedures
Elucidation of the electrophysiological mecha-
nism of AF and atrial flutter (AFL) and the discov-
ery that multiple and changing patterns of reentrant
circuits existed in patients with AF culminated in
a surgical procedure which, in a maze-like manner,
aimed to interrupt all potential circuits that could be
identified by intraoperative mapping. Cox et al. [21]
in 1991 described a surgical procedure now known
as the Maze I procedure, which involved biatrial
excisions, incisions encircling each pulmonary vein,
extensive incisions starting in the right atrium and
extending across the fossa ovalis, incisions from the
inferior aspect of the pulmonary veins to the level
of the mitral valve annulus, and finally cryoablation
at –60°C within the coronary sinus.
Follow-up of patients who had undergone Maze
I revealed significant chronotropic incompetence and
occasional left atrial dysfunction which was thought
to be a result of the incisions placed near the sinus
node [22]. The procedure was modified into the
Maze II procedure, wherein incisions around the si-
nus node were not performed and several altera-
tions where made to the left atrial incisions. This
modification decreased the risk of chronotropic in-
competence but at the same time introduced sig-
nificant new technical challenges making it a long-
er and more complex surgical procedure.
Bachmann’s bundle carries the sinus node im-
pulse rapidly across from the superior septum and
roof of the right atrium to the left atrium and in do-
ing so allows near simultaneous biatrial activation and
respective biventricular filling. Bachmann’s bundle
is either divided or incorporated into the left atrial
roof incisions during the Maze I and II procedures
resulting in a prolonged interatrial conduction time
and AV dyssynchrony particularly between the left
atrium and left ventricle [22]. For this reason, the
procedure was again modified by moving the left atri-
al roof incisions posteriorly (Fig. 1). This apparently
minor modification constituted the Maze III proce-
dure and by doing so dramatically improved the tech-
nical and functional aspects of the procedure [22].
Figure 1. Standard Maze III surgical atrial fibrillation
ablation. Reprinted with permission from Dr. James L.
Cox, MD.
Pulmonary vein





Left atrial appendage lesion
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By July 2000 Cox [23] had reported on 308 pa-
tients who had undergone a surgical Maze III pro-
cedure with an operative mortality rate of 2.9% and
a 37% incidence of post-operative arrhythmia most
commonly AF and AFL. A subsequent 8½-year fol-
low up of 178 patients who had undergone the Maze
procedure showed that 93% remained arrhythmia
free without anti-arrhythmic drug therapy, and the
incidence of a perioperative neurologic event was
only 0.7%; this is thought to be due to closure of
the left atrial appendage [24].
Despite its high success rate of restoring sinus
rhythm, the Maze procedures remain complex, tech-
nically challenging and require long procedure times.
Ongoing research has led to the development of mul-
tiple modifications including minimally invasive ap-
proaches and alternate energy sources aimed at de-
creasing the length of the surgical procedure while
maintaining efficacy in restoring normal sinus rhythm
(Table 1).
Radiofrequency energy
Radiofrequency (RF) energy is an alternating
current that generates heat by causing ions within
tissue to follow the direction of the alternating cur-
rent and in doing so converts electromagnetic en-
ergy to mechanical energy i.e. heat energy. In uni-
polar RF catheters, current flow occurs from the
catheter tip to a surface grounding pad, and so there
is a proportional decline in energy (heat) delivery
to deeper more distal tissues. In bipolar RF cathe-
ters, current flow is between two closely opposed
electrodes limiting energy (heat) flow to small vol-
umes of myocardium. Furthermore, irrigation of RF
catheters with saline serves to cool the electrode
tip helping to decrease the dissipation of heat and
power away from the electrode tip creating deeper
and more uniform lesions. Radiofrequency energy
can be applied to the endocardial and/or epicardial
surfaces. Chiappini et al. [25] reported on 30 pa-
tients who had undergone a surgical Maze III pro-
cedure and 30 patients who underwent RF ablation
for persistent atrial fibrillation. All of the procedures
were performed by a single operator. The two
groups had similar baseline characteristics and were
placed on similar antiarrhythmic drug therapy (pri-
marily amiodarone) post-operatively for up to six
months following surgery. Patients were followed
up for a mean of 15.5 months with the primary end-
point being the restoration of sinus rhythm [25].
The cumulative in-hospital mortality rate was not
statistically different between the two groups, and
the cumulative rates of sinus rhythm were 68.9%
in those treated with the Maze procedure and 88.5%
for those treated with RF ablation [25]. Biatrial con-
traction, assessed at six-month follow up, was
70.4% in those who had undergone surgical Maze
and 76.5% in those treated with RF ablation [25].
Several other groups have demonstrated effective
RF ablation of both paroxysmal and chronic AF
when performed concomitantly during other cardi-
ac surgeries including coronary artery bypass graft-
ing and during valve surgery [26–28].
Microwave energy
Recent use of microwave energy has also proven
to be an effective source of energy for use in cathe-
ter based surgical ablation of AF. Microwave ener-
gies include the spectrum of electromagnetic inten-
sities ranging in frequency from 0.3 to 300 GHz.
Electromagnetic radiation induced by microwave
energy causes molecules to oscillate, transforming
electromagnetic energy into kinetic energy and
eventually thermal necrosis of myocardium. A cath-
eter tip may have one of several different micro-
wave antenna shapes which determine the type of
Table 1. Data obtained from references [35, 42]. Adapted from Bakir et al. [43].
Energy source Mechanism of energy and Clinical use Endocardial/
tissue destruction /epicardial use
Radiofrequency Radiofrequency current Widely used Both
generating thermal destruction
Microwave Electromagnetic waves Expanding use Both
generating thermal destruction
Cryothermy Nitrous argon resulting in ice crystal formation Widely used Endocardial
Ultrasound Sound compression and rarefaction Expanding use Epicardial
generating thermal destruction
Laser Photons of specific wavelength Limited Epicardial
generating thermal destruction
90
Cardiology Journal 2008, Vol. 15, No. 1
www.cardiologyjournal.org
magnetic field generated (Fig. 2). In comparison
to RF energy, larger and deeper lesions can be
created with microwave energy. Lesion sets cre-
ated during microwave energy based AF ablation
are similar to RF ablation based techniques. Beat-
ing heart, minimally invasive microwave energy
based catheters are now being studied as an epi-
cardial ablation tool [29, 30]. Despite the theoret-
ical hope of delivering transmural lesions, a post-
mortem analysis performed by Accord et al. [30]
suggests that the created microwave lesions are
highly variable and are often not transmural in na-
ture. Gillinov et al. [31] have described the use
of microwave energy for AF ablation during mi-
tral valve surgery and Knaut et al. [32] have dem-
onstrated the high safety and efficacy of micro-
wave ablation of PAF during a variety of differ-
ent cardiac surgeries.
Cryothermy
Cryoablation catheters have tips that can be
cooled to –75°C or less, which is achieved by the
infusion of nitrous argon across an area of abrupt
catheter widening. In the Maze III procedure, cry-
othermy is an integral aspect of the procedure and
is used to cryoablate within the coronary sinus.
Cryoablation cools myocardium to specified temper-
atures with resultant intra and extracellular ice
crystal formation causing irreversible cell injury and
eventual necrosis (Fig. 3). The benefits of cryother-
my include the preservation of the underlying cel-
lular architecture and there is also a lower risk of
char and thrombus formation. A phenomenon
termed cryoadhesion, which refers to the catheter
tip sticking to the myocardium during freezing, al-
lows for stable tissue ablation. Repeated cryothermy
Figure 3. Argon based flexible cryoprobe by SurgiFrost Cryocath and a sample cryomap; Cryoablation device.
Irvine, California. Reprinted with permission from CryoCath Technologies.
Figure 2. Microwave ablation catheter. Published with permission from Boston Scientific.
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may be performed to ensure permanent cell injury.
Mack et al. [33] have reported the safe and effec-
tive use of a flexible argon-based cryocatheter dur-
ing concomitant cardiac surgeries. Gaita et al. [34]
compared three different lesion sets in the left atri-
um performed with cryoablation. The lesions sets
consisted of pulmonary vein isolation versus pulmo-
nary vein isolation in addition to one or more linear
ablation lines connecting the inferior pulmonary
veins to the mitral annulus. When compared to cryo-
isolation of the pulmonary veins alone, additional lin-
ear cryoablation lesions were more effective at re-
storing normal sinus rhythm with a success rate as
high as 85% off antiarrhythmic drugs, assuming that
complete electrical block could be achieved. This
study also pointed to the limitations of cryoablation
because even under direct supervision, complete
electrical block could only be achieved in 65% of
patients with linear lesions and in 71% of patients
with pulmonary vein isolation alone [34].
High frequency ultrasound energy
Sound waves propagate in a given medium me-
chanically, through rapidly alternating tension and
compression of this medium. Sound waves with a fre-
quency greater than 20 kHz cannot be detected by the
human ear and are generally considered to be within
the range of ultrasound. High intensity focused ultra-
sound (HIFU) typically has a much higher frequency,
falling in the range of 2–20 MHz. At these far higher
frequencies and with significant power, these short
waves can efficiently heat tissue and while doing so
can be focused to predetermined tissue depths. In
general, the higher the frequency, the better the
myocardium absorbs ultrasonic energy and the sharp-
er the acoustic focusing that can be achieved (Fig. 4).
HIFU waves are created by converting electri-
cal energy into mechanical energy, or piezocrystal
vibrations, through a process called transduction
and is performed by a converting device called
a piezoelectric transducer. These HIFU waves can
be focused, efficiently propagated and targeted to-
wards deeper distant tissues. HIFU waves heat tis-
sue by frictional heating producing the desired ex-
tent of thermal injury in a focal region.
An advantage of using HIFU as an ablation en-
ergy source is its ability to overcome the heat sink
effect of the left atrial blood pool allowing the crea-
tion of transmural lesions when delivered from the
epicardial surface. The ability to focus tissue de-
struction to specific depths allows for safe epicar-
dial ablation of the left atrial isthmus, which is in
close proximity to the left circumflex artery. HIFU
can effectively ablate myocardium without having
to dissect epicardial fat and in theory without con-
cern for coronary artery injury. Because of the
mechanics of HIFU energy deposition, and unlike
thermal-gradient radiofrequency, microwave, laser
or cryoablation, the amount of tissue ablated is lim-
ited to the tissue located within the base width of
the transducer (ablation device).
In a prospective multicentre trial involving five
European centres, off-pump epicardial HIFU abla-
tion was used to perform single-step circumferen-
tial pulmonary vein isolation on the beating hearts
of 103 patients during concomitant cardiac surgery,
of whom 76 (74%) had permanent AF, 22 (21%) had
paroxysmal AF and 5 (5%) had persistent AF [35].
Using a HIFU ablation device, pulmonary vein
isolation was achieved in an average time of ten
minutes. Using a second HIFU ablation device, an
additional epicardial mitral line connecting the left
pulmonary veins to the mitral annulus was
Figure 4. Epicor(tm) cardiac ablation system. High intensity focused ultrasound ablation system. Images are copyright
2007, St. Jude Medical, Inc. Reprinted with permission.
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performed in 34 (35%) patients. There were no re-
ported device or ablation related complications and
no deaths occurred during the trial. At six-month
follow-up, freedom from AF, as measured by both
surface ECG and 24-hour Holter monitoring, was
85% in the entire study group, 88% in the 35 pa-
tients who had the additional mitral line, and 100%
in patients with PAF [35].
Laser
Light amplification by stimulated emission of
radiation (LASER) is a beam of light with a well-
defined wavelength that can be precisely focused,
generating heat and tissue destruction. Using a la-
ser energy source, surgical AF ablation has been
described in a dog model. Complete pulmonary vein
isolation was performed on 16 dogs and an average
of 5.6 ± 0.82 lesions were performed to complete
the isolation; each lesion was 45 s in duration [36].
Histochemical analysis showed all lesions to be
transmural [36]. Currently there is no human data
available with respect to the use of laser energy
during surgical AF ablation.
Alternative energy sources
versus Maze III
Khargi et al. [37] reviewed the efficacy of al-
ternative energy sources (radiofrequency, micro-
wave, cryothermy) versus the classic Maze III pro-
cedure in the surgical treatment of AF. There were
2279 patients who had undergone surgical ablation
with an alternative energy source and 1153 patients
who had undergone surgical Maze III. Postoperative
SR rates with alternative energy sources compared
to Maze III were 78.3% vs. 84.9% (p = 0.03) [37].
However, after controlling for type and duration of
AF, and for the presence and type of concomitant
cardiac surgery, the difference was no longer sig-
nificant (p = 0.260) [37].
More recently, Stulak et al. [38] reported on
a comparison between 56 patients who underwent
surgical Cox Maze ablation using bipolar RF ener-
gy and 56 matched control patients who underwent
classic cut-and-sew Cox Maze. Patients undergo-
ing RF ablation were less likely to be free from AF
at discharge (64% vs. 88%, p = 0.0039) and at last
follow-up (62% vs. 92%, p = 0.016). According to
multivariate analysis, patients receiving RF ablation
were 4.5 times more likely to be in AF at the time
of hospital discharge.
Biatrial versus left atrial
only surgical ablation
Since its initial inception in 1987, the Cox Maze
procedure has undergone numerous modifications
and is the focus of ongoing research trying to iden-
tify the safest and most effective lesion sets. Bar-
nett and Ad [39]. performed a meta-analysis com-
paring the safety and effectiveness of AF surgical
elimination procedures involving biatrial lesions
versus left atrial only lesions. Sixty-nine studies
were included in the analysis, comprising 5885 pa-
tients in total with survival data reported up to three
years. Patients undergoing any surgical AF ablation
procedure were more likely to be free from AF
(90.4–85.4%) compared to controls (47.2–60.9%).
At all time points, patients undergoing biatrial le-
sion sets had a higher rate of freedom from AF
(92.0–87.1%) compared to patients receiving left
atrial only lesions (86.1–73.4%), although survival
was similar [39].
Stroke rate and long-term anticoagulation
following surgical Maze procedure
The stroke rate following Maze procedure is
reported to be as low as 0.1% per year, due in part
to the restoration of atrial transport function and
atrioventricular synchrony thereby minimizing in-
tracardiac stasis and the formation of intracardiac
thrombi [40, 41]. Another contributing factor to the
reduction of stroke events is the excision or liga-
tion of the left atrial appendage during a Cox Maze
procedure [41].
Use of anticoagulation following a Cox Maze
procedure is in part determined by the type of con-
comitant cardiac surgery, if any. In a series of
306 patients, 45 required permanent anticoagulation
with warfarin, and this included patients with any
type of mitral prosthesis, patients with mechanical
aortic valves and those in whom a Bentall procedure
was performed. In this same series, 78 patients
received temporary warfarin anticoagulation for
a period of three months only because of a preoper-
ative thromboembolic event, and 142 patients re-
ceived no warfarin therapy at all [41]. At 11.5 years
of follow up, the overall stroke rate was 0.4% [41].
Conclusions
The aim of surgical AF ablation is to achieve
safe and effective arrhythmia control, potentially
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obviating the need for antiarrhythmic and antico-
agulation therapies. Our understanding of the patho-
electrophysiology of AF has significantly improved
over the past 40 years and with this new under-
standing we have seen the development and evo-
lution of new surgical techniques and energy sourc-
es for ablating AF. Ongoing trials and registries will
hopefully shed further light on identifying which
patients need to consider surgical AF ablation, and
at what point clinicians need to as well.
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